Dimension Therapeutics聽announced it will聽discontinue the development of DTX101, an investigational AAVrh10-based gene therapy product in development for the treatment of moderate/severe-to-severe hemophilia B. The decision followed the review of the emerging DTX101 Phase 1/2 clinical study data, including the data as of the beginning of聽May 2017, and the observation that the data would not meet the company鈥檚 minimum target product profile for continued development or future commercialization. Click here to read the press release in full from Dimension Therapeutics.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.